Creatine & Brain Bioenergetics

Creatine is a nitrogenous organic acid synthesized endogenously from glycine, arginine, and methionine in the liver, kidneys, and pancreas, and obtained in the diet almost exclusively from animal flesh (red meat and fish supply roughly 1–2 g/day in omnivores; vegetarians and vegans run measurably lower stores). About 95% of the body's creatine pool resides in skeletal muscle, but the fraction that interests psychiatry is the small, metabolically critical reserve in brain. There, creatine and its phosphorylated form, phosphocreatine, function as a spatial and temporal energy buffer — a rechargeable battery that regenerates ATP from ADP on a millisecond timescale via creatine kinase, smoothing the gap between fluctuating neuronal energy demand and slower mitochondrial supply.

Creatine has moved from the gym to the clinic precisely because depression increasingly looks, in part, like a disorder of cerebral energy metabolism. It is the most direct nutraceutical embodiment of the bioenergetic hypothesis of mood disorders, and the single supplement most tightly coupled to this library's mitochondrial-dysfunction and fatigue accounts.

Proposed Mechanism

The mechanistic case rests on convergent neuroimaging and metabolic findings.

Phosphocreatine depletion in depression. ³¹P-magnetic resonance spectroscopy studies report altered high-energy phosphate metabolism in depressed brain — reduced phosphocreatine and abnormal pH and ATP dynamics, particularly in frontal regions. The deficit is more pronounced and more consistently reported in women. Oral creatine supplementation demonstrably raises brain phosphocreatine (shown by Lyoo and colleagues using ³¹P-MRS), establishing target engagement — the supplement reaches the organ of interest and changes the metabolite it is hypothesized to act on. This is a level of mechanistic confirmation most nutraceuticals never achieve.

Why a bioenergetic deficit would manifest as depression. Neurons are extraordinarily energy-hungry; the brain consumes ~20% of resting metabolic rate. Regions implicated in mood and motivation — prefrontal cortex, anterior cingulate, striatum — sustain high tonic firing and rapid demand transients. A degraded phosphocreatine buffer would preferentially impair exactly the effortful, sustained processing that anhedonia, avolition, psychomotor slowing, and cognitive fatigue reflect. Creatine thus offers a unifying substrate-level account of the somatic and motivational symptom cluster.

Secondary mechanisms. Creatine has antioxidant properties and may stabilize mitochondrial membrane potential and buffer against excitotoxic and oxidative insults. It modulates NMDA-receptor and glutamatergic signaling and may influence neuroplasticity downstream. The bioenergetic and antioxidant stories are complementary rather than competing: a better-buffered, less oxidatively stressed neuron is also a more plastic one.

The sex-difference signal. The recurring observation that brain creatine effects and clinical benefit are larger in women is mechanistically interesting — it may reflect baseline sex differences in brain creatine kinetics, creatine kinase activity, or dietary intake — and clinically practical, since it nominates a candidate responder subgroup.

Evidence Base

The creatine literature is small, recent, and a near-ideal teaching case in how to read a promising-but-immature evidence base honestly.

The augmentation trials. The most cited positive result is Lyoo and colleagues (2012): in women with MDD, 5 g/day of creatine added to an SSRI produced faster and greater improvement than SSRI plus placebo, with separation emerging early. Kondo and colleagues studied adolescent females (a dose-finding design, 2/4/10 g) with encouraging results. Smaller trials added creatine to electroconvulsive therapy (Kious/Renshaw) and, more recently, to cognitive-behavioral therapy (Sherpa et al., 2025), the latter reporting greater PHQ-9 reduction with creatine plus CBT than CBT plus placebo — an intriguing hint that bioenergetic support might potentiate the demanding cognitive work of psychotherapy.

The 2025 meta-analytic reckoning. The most rigorous synthesis to date (Eckert et al., British Journal of Nutrition, 2025) pooled 11 RCTs and 1,093 participants. The result is a model of how this series weighs evidence: a statistically detectable but clinically sub-threshold effect — SMD −0.34 (95% CI −0.68 to −0.00), equivalent to roughly 2.2 points on the 17-item Hamilton scale, below the ~3-point minimal clinically important difference. The confidence interval brushed zero. Heterogeneity was substantial (I² ≈ 71%). Remission was more frequent with creatine across three trials, but — crucially — trim-and-fill and subgroup analyses indicated substantial bias favoring creatine, and GRADE certainty was rated very low. Effects looked larger in clinically depressed (versus non-depressed) samples, which is at least directionally reassuring.

Supporting observational data. A large NHANES cross-sectional analysis found an inverse association between dietary creatine intake and depression prevalence after adjustment — biologically suggestive, causally inert, and vulnerable to reverse causation and residual confounding.

The honest synthesis: creatine is mechanistically the most compelling nutraceutical for mood in this series, with genuine target engagement and a coherent bioenergetic rationale, yet its clinical evidence remains thin, biased toward positive, and below the threshold of demonstrated meaningful benefit. It is a strong hypothesis awaiting an adequately powered, registered, bias-resistant trial — ideally enriched for women and for patients with somatic/fatigue-predominant presentations.

Who Might Benefit / Indications

The most defensible use is adjunctive creatine in patients with MDD who have a partial antidepressant response, with the strongest a priori rationale in women and in presentations dominated by fatigue, anergia, psychomotor slowing, and cognitive sluggishness rather than guilt or anxiety. Vegetarians and vegans, who carry lower baseline brain creatine stores, are a theoretically enriched responder group. Creatine is also a reasonable consideration where mitochondrial or bioenergetic contributors are suspected. It should not displace first-line treatment, and the evidence does not support it as monotherapy for moderate-to-severe depression.

Formulation, Dosing & Bioavailability

Creatine monohydrate is the form to use — it is the most studied, the cheapest, and the benchmark against which every "advanced" form (HCl, buffered, ethyl ester) is marketed without demonstrated superiority. The psychiatric trials almost uniformly used monohydrate at a median 5 g/day. A loading phase (≈20 g/day for 5–7 days) saturates muscle stores faster but is not necessary for brain effects and increases GI complaints; steady 3–5 g/day reaches saturation over ~3–4 weeks. Brain uptake is slower and less complete than muscle uptake, which is part of why an adequate trial runs 4–8 weeks minimum. Co-ingestion with carbohydrate modestly enhances uptake via insulin but is not essential. Choose products carrying a Creapure or equivalent purity certification, since creatine is a commodity vulnerable to contamination with creatinine, dicyandiamide, and dihydrotriazine during manufacture.

Safety & Interactions

Creatine monohydrate is one of the most extensively safety-studied supplements in existence, with a reassuring record across decades of sports-medicine use. The common effects are benign: water retention and a 1–2 kg weight increase (intracellular fluid, frequently misread by patients as fat gain — worth pre-empting), occasional GI upset and cramping at higher doses or during loading. The persistent lay belief that creatine harms the kidneys is not supported in individuals with normal renal function; it does, however, modestly raise serum creatinine by a non-pathological mechanism (it is a creatine metabolite), which can confound eGFR interpretation — a clinically relevant point when ordering or reading renal panels in a supplementing patient. Genuine caution is appropriate in pre-existing renal disease. There are no important pharmacokinetic drug interactions. A theoretical and occasionally reported concern is increased irritability or activation in bipolar patients (consistent with creatine augmenting energy/activation); use with the same caution applied to any potentially activating agent in bipolar depression.

Convergence

Creatine is the keystone of the bioenergetic account that runs through mitochondrial dysfunction, fatigue, and the somatic pole of anhedonia and avolition. Its antioxidant action connects to oxidative stress; its glutamatergic and plasticity effects route into glutamatergic dysfunction and the neuroplasticity common pathway. Within this series it pairs naturally with omega-3 (membrane plus energetics) and shares its "mechanism ahead of trials" status with much of the field.

Caveats

Creatine is where mechanistic elegance most outruns clinical proof in this series — and resisting the pull of that elegance is the discipline the evidence demands. Target engagement is confirmed and the rationale is excellent, but the pooled clinical effect is below the minimal important difference, the confidence interval includes nothing, heterogeneity is high, and the bias-correction analyses point the wrong way. The sex-difference and symptom-subtype signals that make the story compelling are hypothesis-generating, not validated treatment-selection criteria. The appropriate stance is calibrated optimism: a cheap, safe, mechanistically grounded adjunct worth trialing in the right patient, described to that patient with honest uncertainty rather than as an established antidepressant.

Bottom Line

Creatine monohydrate (5 g/day, 4–8+ week trial) is a safe, inexpensive, mechanistically well-grounded adjunct for MDD, with the best rationale in women and in fatigue/anergia-predominant presentations. It uniquely offers confirmed brain target engagement (raises phosphocreatine), yet its clinical evidence remains very-low-certainty and, on the best current meta-analysis, below the threshold of demonstrated meaningful benefit. A promising hypothesis worth acting on cautiously — and worth watching for the adequately powered trial it deserves. Remember to interpret serum creatinine and eGFR in light of supplementation.

Key References

1. Eckert I, Lima J, Dariva AA, et al. Creatine supplementation for treating symptoms of depression: a systematic review and meta-analysis. Br J Nutr. 2025.
2. Lyoo IK, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to an SSRI in women with major depressive disorder. Am J Psychiatry. 2012.
3. Kondo DG, et al. Creatine target engagement and dose-finding in adolescent females with treatment-resistant depression. Amino Acids / J Affect Disord.
4. Kious BM, Kondo DG, Renshaw PF. Creatine for the treatment of depression. Biomolecules. 2019.
5. Sherpa NN, et al. Creatine augmentation of cognitive-behavioral therapy for depression: a randomized trial. 2025.
6. Juneja K, et al. Creatine supplementation in depression: a review of mechanisms, efficacy, clinical outcomes, and future directions. Cureus. 2024.
7. Allen PJ. Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value? Neurosci Biobehav Rev. 2012.
8. Pazini FL, Cunha MP, Rodrigues ALS. The bioenergetic and antioxidant status of creatine in depression. Mol Neurobiol. 2019.
9. Avgerinos KI, et al. Effects of creatine supplementation on cognitive function in healthy individuals: a systematic review and meta-analysis. Exp Gerontol. 2018.
10. Roschel H, Gualano B, et al. Creatine supplementation and brain health. Nutrients. 2021.
11. Bakian AV, et al. Dietary creatine intake and depression risk (NHANES). Transl Psychiatry. 2023.
12. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022.
13. Toniolo RA, et al. Creatine supplementation in bipolar depression. J Affect Disord. 2017.
14. Kreider RB, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation. J Int Soc Sports Nutr. 2017.
15. Forbes SC, et al. Creatine supplementation and brain creatine/phosphocreatine: ³¹P-MRS evidence. 2022.
16. Firth J, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review. World Psychiatry. 2019.